AU2022251843B2 - <i>A PI3K-DELTA INHIBITOR FOR USE IN TREATMENT REGIMENS</i> - Google Patents

<i>A PI3K-DELTA INHIBITOR FOR USE IN TREATMENT REGIMENS</i>

Info

Publication number
AU2022251843B2
AU2022251843B2 AU2022251843A AU2022251843A AU2022251843B2 AU 2022251843 B2 AU2022251843 B2 AU 2022251843B2 AU 2022251843 A AU2022251843 A AU 2022251843A AU 2022251843 A AU2022251843 A AU 2022251843A AU 2022251843 B2 AU2022251843 B2 AU 2022251843B2
Authority
AU
Australia
Prior art keywords
salt
compound
formula
cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2022251843A
Other languages
English (en)
Other versions
AU2022251843A1 (en
Inventor
Zoë JOHNSON
Michael LAHN
Catherine PICKERING
Lars Van Der Veen
Rebeca ZORRILLA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionctura SA
Original Assignee
Ionctura SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2104416.9A external-priority patent/GB202104416D0/en
Priority claimed from GBGB2117511.2A external-priority patent/GB202117511D0/en
Application filed by Ionctura SA filed Critical Ionctura SA
Publication of AU2022251843A1 publication Critical patent/AU2022251843A1/en
Application granted granted Critical
Publication of AU2022251843B2 publication Critical patent/AU2022251843B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
AU2022251843A 2021-03-29 2022-03-29 <i>A PI3K-DELTA INHIBITOR FOR USE IN TREATMENT REGIMENS</i> Active AU2022251843B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB2104416.9 2021-03-29
GBGB2104416.9A GB202104416D0 (en) 2021-03-29 2021-03-29 Treatment reginmens
GBGB2117511.2A GB202117511D0 (en) 2021-12-03 2021-12-03 Treatment regimens
GB2117511.2 2021-12-03
PCT/EP2022/058283 WO2022207646A1 (en) 2021-03-29 2022-03-29 A pi3k-delta inhibitor for use in treatment regimens

Publications (2)

Publication Number Publication Date
AU2022251843A1 AU2022251843A1 (en) 2023-10-05
AU2022251843B2 true AU2022251843B2 (en) 2026-04-09

Family

ID=81388915

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022251843A Active AU2022251843B2 (en) 2021-03-29 2022-03-29 <i>A PI3K-DELTA INHIBITOR FOR USE IN TREATMENT REGIMENS</i>

Country Status (17)

Country Link
US (2) US12605389B2 (cg-RX-API-DMAC7.html)
EP (2) EP4313058B1 (cg-RX-API-DMAC7.html)
JP (1) JP7839803B2 (cg-RX-API-DMAC7.html)
AU (1) AU2022251843B2 (cg-RX-API-DMAC7.html)
CA (1) CA3212731A1 (cg-RX-API-DMAC7.html)
DK (1) DK4313058T3 (cg-RX-API-DMAC7.html)
ES (1) ES3031295T3 (cg-RX-API-DMAC7.html)
FI (1) FI4313058T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250516T1 (cg-RX-API-DMAC7.html)
HU (1) HUE071610T2 (cg-RX-API-DMAC7.html)
LT (1) LT4313058T (cg-RX-API-DMAC7.html)
MX (1) MX2023011442A (cg-RX-API-DMAC7.html)
PL (1) PL4313058T3 (cg-RX-API-DMAC7.html)
PT (1) PT4313058T (cg-RX-API-DMAC7.html)
RS (1) RS66754B1 (cg-RX-API-DMAC7.html)
SI (1) SI4313058T1 (cg-RX-API-DMAC7.html)
WO (1) WO2022207646A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024184266A1 (en) * 2023-03-03 2024-09-12 Ionctura Sa Combination of roginolisib and hdac inhibitor in the treatment of haematological malignancy
JP2026510567A (ja) * 2023-03-03 2026-04-08 アイオンクチュラ・ソシエテ・アノニム 血液悪性腫瘍の治療におけるロギノリシブ及びbcl-2阻害剤の組み合わせ
GB202418087D0 (en) 2024-12-10 2025-01-22 Ionctura Sa Biomarkers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011058149A1 (en) * 2009-11-13 2011-05-19 Merck Serono S.A. Tricyclic pyrazol amine derivatives
WO2014121901A1 (en) * 2013-02-07 2014-08-14 Merck Patent Gmbh Polymorphic forms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9986723B2 (en) 2014-10-22 2018-06-05 The Board Of Regents Of The University Of Texas System Screen and use of therapeutics for pancreatic ductal adenocarcinoma
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
US20200088732A1 (en) 2017-04-13 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Mèdicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011058149A1 (en) * 2009-11-13 2011-05-19 Merck Serono S.A. Tricyclic pyrazol amine derivatives
WO2014121901A1 (en) * 2013-02-07 2014-08-14 Merck Patent Gmbh Polymorphic forms

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MACQUEEN AMY R., VITICCHIE GIUDITTA, NIEWOLA KAROLINA, FINOTELLO FRANCESCA, POWLEY IAN, SHAH PRITOM, VAN DER VEEN LARS, LAHN MICHA: "Abstract 666: A novel, highly selective PI3Kδ inhibitor for the treatment of solid malignancies that express high levels of target protein as assessed by immunohistochemistry", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR), vol. 80, no. 16_Supplement, 15 August 2020 (2020-08-15), pages 666 - 666, XP055941409, ISSN: 0008-5472, DOI: 10.1158/1538-7445.AM2020-666 *

Also Published As

Publication number Publication date
CA3212731A1 (en) 2022-10-06
US20260224587A1 (en) 2026-08-06
PT4313058T (pt) 2025-06-02
LT4313058T (lt) 2025-05-26
RS66754B1 (sr) 2025-05-30
HRP20250516T1 (hr) 2025-06-20
SI4313058T1 (sl) 2025-07-31
DK4313058T3 (da) 2025-05-12
EP4744651A2 (en) 2026-05-20
ES3031295T3 (en) 2025-07-07
US20240058351A1 (en) 2024-02-22
HUE071610T2 (hu) 2025-09-28
PL4313058T3 (pl) 2025-06-23
FI4313058T3 (fi) 2025-04-30
MX2023011442A (es) 2023-10-18
JP2024518685A (ja) 2024-05-02
AU2022251843A1 (en) 2023-10-05
EP4313058B1 (en) 2025-03-05
WO2022207646A1 (en) 2022-10-06
JP7839803B2 (ja) 2026-04-02
EP4313058A1 (en) 2024-02-07
US12605389B2 (en) 2026-04-21

Similar Documents

Publication Publication Date Title
US12605389B2 (en) PI3K-δ inhibitor for use in treatment regimens
US20160287588A1 (en) Methods of treating a bruton&#39;s tyrosine kinase disease or disorder
EP3695839A1 (en) Therapeutic agent for solid cancers, which contains axl inhibitor as active ingredient
JP6058009B2 (ja) Pi3k−およびmek−阻害剤の相乗的な組合せ
EA032430B1 (ru) Конденсированные пиримидины для лечения вич
KR20150141971A (ko) 이브루티닙 병용 요법
US9682082B2 (en) Combinations of AKT and MEK inhibitor compounds, and methods of use
CN110636844A (zh) 使用ccr3-抑制剂治疗衰老相关损伤的方法及组合物
KR20160004272A (ko) 전립선암 치료를 위한 디하이드로피라지노-피라진 화합물 및 안드로겐 수용체 길항제를 포함하는 조합요법
TW202033191A (zh) 新穎藥物組成物及其用途
WO2019224774A1 (en) Heterocyclic amides as rip1 kinase inhibitors
US20140142129A1 (en) Methods of treating a disease or disorder associated with bruton&#39;s tyrosine kinase
AU2022250707B2 (en) A pi3k-delta inhibitor for the treatment of pancreatic cancer
US20140142128A1 (en) Methods of treating a disease or disorder associated with bruton&#39;s tyrosine kinase
US20140140991A1 (en) Methods of treating a disease or disorder associated with bruton&#39;s tyrosine kinase
KR101739158B1 (ko) 조합물
TW202508597A (zh) 一種呱嗪衍生物的藥物製劑、其製備方法及其用途
EP3125935B1 (en) Combinations of cancer therapeutics
WO2024151930A1 (en) Pi3k inhibitors and methods of making and using the same
CN117042778A (zh) 用于治疗方案的PI3K-δ抑制剂
WO2016006621A1 (ja) Pgd2拮抗剤を含有するアレルギー性疾患に伴う症状の治療用医薬
KR20180112066A (ko) 피롤로-융합된 6-원의 헤테로시클릭 화합물을 포함하는 약학적 조성물
AU2012321091A1 (en) Methods of treating a Bruton&#39;s Tyrosine Kinase disease or disorder
NZ617243B2 (en) Combinations of akt and mek inhibitor compounds, and methods of use
WO2013039197A1 (ja) IκBキナーゼα活性化阻害剤

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)